Kornimate/medical-research-clean huggingface dataset:
predictive value of admission blood glucose level in patients with acute myocardial infarction

Conditions: Predictive Value of Admission Blood Glucose Level in Acute Myocardial Infarction

Summary: coronary atherosclerosis is the leading cause of death worldwide. diabetes mellitus is associated with increased prevalence of coronary artery disease increased plasma glucose is a common feature in the acute phase of myocardial infarction, even in patients without diabetes. patients with stress hyperglycemia, but without previous diagnosis of diabetes, were at increased risk of congestive heart failure, arrhythmia and cardiogenic shock as well as increased both in-hospital and long-term mortality . previous studies have demonstrated larger infarct size and poorer prognosis inpatients with hyperglycemia upon hospital admission compared with patients without hyperglycemia it has been reported that stress hyperglycemia impairs microvascular circulation and may lead to no-reflow phenomenon. no reflow phenomenon was significantly more frequent among patients with hyperglycemia and increased progressively with increasing admission blood glucose in patients with acute myocardial infarction . furthermore, patients with high admission glucose are more likely to develop restenosis and require repeat revascularization procedures compared with those with normal admission glucose and are also at increased risk for repeated myocardial infarction, stent thrombosis and death.


Eligibility criteria:
inclusion criteria: acute st segment elevation myocardial infarction patients not known to have diabetes mellitus undergoing primary pci. exclusion criteria: * patients known to have diabetes mellitus (known diabetes mellitus on admission, which was treated with diet, oral glucose-lowering medication, and/or insulin). * patients with prior primary percutaneous intervention and/or coronary artery bypass graft (altering disease state). * patients with severe liver or renal disease (altering disease state). * patients with anemia, kidney disease or certain blood disorders (thalassemia).
observational study in patients suffering from benign prostatic hyperplasia treated with alpha-adrenergic blockade

Conditions: Prostatic Hyperplasia

Summary: the primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with bph who were administered class-1 alpha blockers. the secondary objectives were the assessment of the time from alpha-adrenergic blockade treatment initiation to surgery and the evolution of patients during the study.


Eligibility criteria:
inclusion criteria: * any patient with bph for whom alpha-blocker treatment is indicated * patients who are already on class-1 alpha-blockers can only participate in the study if all information required is known and/or available exclusion criteria: * patient's follow-up not possible * patients participating in another study * history of bph surgery * prostate cancer
new heart failure biomarkers in early stage chronic kidney disease-mineral and bone disorder

Conditions: Kidney Disease, Chronic; Heart Failure

Summary: the objective of this study is to : -determinate wether the circulating levels of ifgf23 and klotho can be a predictor biomarker of hf in patients with ckd-mbd.

the disorders of mineral metabolism and bone disease are common complications in ckd patients and they are associated with increased morbidity and mortality. abnormalities of the vasculature are seen in early ckd, producing vascular stiffness contributing to left ventricular hypertrophy and its pathophysiology involves newly discovered hormones, such as the fibroblast growth factor 23 (fgf23) and α- klotho. the fgf receptor and its co-receptor klotho moderate these effects. fgf23 levels inflate early in in the advancement of ckd stage to attain levels in ckd stage 5d. but we still have few knoweledges if these markers can have some drawbacks for predicting cvd in early stage ckd.

Eligibility criteria:
inclusion criteria: * early ckd stage * heart failure exclusion criteria: * infections * cancer * corticoid therapy * renal replacement therapy * advanced ckd stage

Keywords: fgf23 klotho mineral bone disorder
comparison of two treatments to prevent invasive fungal infections in patients who have received liver transplants

Conditions: Candidiasis

Summary: the purpose of this study is to compare the safety and effectiveness of 2 treatments to prevent invasive fungal infections (ifi), which are infections caused by yeasts and molds that are common in patients with weak immune systems or transplant patients. ambisome, a new treatment, will be compared to fluconazole, the traditional treatment for fungal infections caused by the yeast candida. treatment will only be given to liver transplant patients who are found to be at high risk for ifi. liver transplant patients who are at low risk for ifi will be monitored but will receive no study medication. ifis are found mainly in a high risk group of liver transplant patients, and are not common in those with low risk. if ifi preventive therapy is focused on the high risk group, there may be a lesser chance of candida becoming resistant (able to grow despite the presence of drugs used to kill it). treating only the high risk group will also save money.

if you are in the high risk group you will be assigned randomly (like tossing a coin) to receive either ambisome or fluconazole. if you are in the low risk group, you will not receive any treatment. both groups will be monitored for ifis. the study will last for 100 days following your liver transplant.

Eligibility criteria:
inclusion criteria: you may be eligible for this study if you: * have had a liver transplant within 5 days of enrollment and agree to receive tacrolimus. exclusion criteria: you will not be eligible for this study if you: * are hiv-positive. * have a history of invasive fungal infection. * have received antifungal agents within 14 days prior to your liver transplant. * are allergic to azoles, amphotericin b, or tacrolimus.
outcomes of endoscopic resection of mucosal and submucosal lesions in the stomach

Conditions: Adenoma, Villous

Summary: a patient referred to have a lesion in the stomach removed. the aims of this study are to collect information on the technique of endoscopic removal of such lesions. by collecting information on a large number of patients undergoing this procedure the investigators can determine the best ways of diagnosing and removing these lesions safely and effectively.


Eligibility criteria:
inclusion criteria: * stomach lesion \> 10mm * lesion limited to the mucosal and/or submucosal layer (t1 lesion) * aged 18 years or older exclusion criteria: * lesion less than 10mm * stomach lesion involves the muscularis propria (t2 lesion) on other staging modalities such as endoscopic ultrasonography (eus) * aged younger than 18 years
perioperative inflammatory response assessment in high-risk patients undergoing noncardiac surgery

Conditions: Postoperative Complications; Cardiovascular Complication; Myocardial Ischemia; Inflammation

Summary: postoperative cardiovascular complications are common after noncardiac surgery. the association between perioperative inflammation and the occurrence of cardiovascular complications after surgery is still unknown. therefore, we will evaluate as our primary aim the association between patients with increased postoperative inflammation, assessed with c-reactive protein measurements, and the occurrence of major cardiovascular complications after noncardiac surgery. we will further evaluate the influence of perioperative inflammation on the occurrence of postoperative acute kidney injury. we will also evaluate the association between inflammation and the influence on days-at-home within 30 days. furthermore, we will evaluate the association between increased inflammatory biomarkers and postoperative n-terminal pro brain natriuretic peptide (nt-probnp) concentration.


Eligibility criteria:
all patients need to meet all of the following criteria for inclusion (1-4): 1. surgery planned for more than two hours 2. ≥ 45 years of age 3. provide written informed consent and 4. fulfill ≥ 1 of the following criteria (a-k) inclusion criteria: * nt-probnp ≥ 200 ng/l * troponin t \> 25 ng/l * history of coronary artery disease * history of peripheral artery disease (pad) * 75 years or older * history of transient ischemic attack (tia) or stroke * current smoking or cessation of smoking within 2 years * diabetes or currently taking anti-diabetic drug * hyperlipidemia * history of hypertension or currently taking an antihypertensive drug * atrial fibrillation exclusion criteria: * patients on immune-suppressive therapy * icu patients undergoing surgery * preoperative sepsis/systemic inflammatory syndrome (sirs) needing icu treatment * preoperative hemodynamically instable patients, who require vasopressor or inotropic support * history of severe heart failure (defined as left ventricular ejection fraction (lvef) \< 30%) * liver cirrhosis * chronic inflammatory bowel diseases (cibd) * severe rheumatic diseases requiring immunosuppressive treatment
comparison of central and peripheral venous catheters

Conditions: Respiratory Insufficiency; Shock; Coma

Summary: the purpose of this study is to compare the mechanical and infectious complications of peripheral versus central venous catheters in critically ill patients. group allocation will be performed by randomization.

critically ill patients require intravenous administration of fluids and drugs. this can be achieved via peripheral or central catheters. each device is associated with both mechanical and infectious complications. complications associated with central lines are judged to be more severe. some patients actually require the insertion of a central line due to the venous toxicity of the drugs or to the necessity of making sure that the infusion is regularly administered (example: high dose catecholamine infusion). some physicians believe that most intensive care unit (icu) patients should have a central venous line inserted, whereas others feel that some patients may receive active drugs via a peripheral line in selected instances. no study prospectively compared the feasibility, merits and complications of the two possibilities (i.e., central or peripheral venous line). this study includes patients that can receive either a central or a peripheral line (see inclusion criteria): mainly patients receiving large amounts of fluid, moderate doses of catecholamines or of drugs that may cause venous injury. patients are randomized to receive either a peripheral or a central venous catheter. endpoints are the rate of mechanical complications (difficulty in inserting the line, need for repeat insertion attempts, occurrence of arterial puncture, occurrence of pneumothorax) and of infectious complications (local catheter infection or catheter-related bloodstream infection).

Eligibility criteria:
inclusion criteria: * patients requiring low to moderate doses of continuous catecholamine administration in the icu * patients with 2 failed attempts at inserting a peripheral line * patients who require daily change of lines exclusion criteria: * patients aged less than 18 years * pregnancy * absolute necessity of central venous access (refractory shock/high dose catecholamine infusion)

Keywords: catheter-related infection mechanical complications of catheters
clinical trial to evaluate the efficacy and safety of da-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

Conditions: Diabetes Mellitus

Summary: this study is a multicenter, double-blind, active-controlled, randomized, parallel, phase iv clinical trial to evaluate the efficacy and safety of da-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control


Eligibility criteria:
inclusion criteria: * subjects with 7.0%≤hba1c≤10.0% at screening * subjects treated with 1,000mg/day or higher dose of metformin for at least 8 weeks prior to screening * subjects with 18.5kg/m2≤bmi≤40kg/m2 at screening * subject who is willing and able to provide informed consent indicating that they understand the purpose and procedures required for the study exclusion criteria: * subjects with fasting plasma glucose≥240mg/dl at screening * patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus * subject with alt and ast 3 times or higher than upper normal range * subject with history of myocardial infarction, cerebral infarction within 3 months prior to screening
impact of antiretroviral treatment on pharmacokinetics and pharmacodynamics of thienopyridines in healthy volunteers and hiv patients

Conditions: Hiv

Summary: hiv patients are at particular risk to develop cardiovascular disease (cvd) as they exhibit multiple risk factors by the nature of their pathology. in addition, the long term exposition to antiretroviral drugs has been associated to an increased risk for cvd. hiv patients can thus potentially receive antiplatelet therapy concomitantly with their antiretroviral treatment. clopidogrel and prasugrel are thienopyridine antiplatelet agents indicated to prevent the recurrence of ischemic events after coronary arteries stenting. these pro-drugs are mainly bioactivated by cytochromes p450 (cyp) 3a and 2b6 for prasugrel and cyp2c19, cyp3a and cyp2b6 for clopidogrel. ritonavir is commonly used to "boost" the bioavailability of other hiv drugs through inhibition of cyp3a4 as well as cyp2b6 and cyp2c9. this interaction could therefore reduce clopidogrel and prasugrel efficacy by reducing the formation of their active metabolites. the aim of the present study is to assess the potential drug-drug interaction between clopidogrel/prasugrel and ritonavir. two groups of 12 male subjects will be constituted (12 hiv patients under ritonavir boosted therapy and 12 healthy volunteers) in a randomized cross-over clinical trial. all subjects will also be genotyped for the cyp2c19. the pharmacokinetics of clopidogrel active metabolite and prasugrel active metabolite will be assessed. furthermore, the pharmacodynamic response will be evaluated by two gold standard platelet inhibition tests, namely vasodilator-stimulated phosphoprotein assay (vasp) and verifynow® assays. the primary endpoint of this study is to compare the pharmacodynamic response to clopidogrel and prasugrel in hiv patients to that of healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy males \>18 years * understanding of french language and able to give an inform consent * anti-hiv therapy with ritonavir or cobicistat (for hiv group) * stable antiretroviral treatment since at least 2 weeks (for hiv group) * viremia \<100 copies/ml (for hiv group) exclusion criteria: * renal failure: calculated creatinine clearance (cockcroft) \< 50ml/min * hepatic impairment (asat, alat, bilirubin, gamma-gt more than 2-fold increase) * smoker \>1 pack/day * hypersensitivity to any of the drugs used * intake of any drug or particular food (grapefruit) that can affect cyp activities inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake) * pathologies or drugs associated with an increased bleeding risk such as aspirin, non-steroidal anti-inflammatory drugs, steroids and serotonin reuptake inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake) * bleeding familial history or antecedent or haemorrhagic disease
addressing the social needs of children with obesity

Conditions: Obesity, Childhood

Summary: this study aims to improve the treatment of a common, chronic health concern for children: obesity. it has the potential to improve the care we provide by testing an intervention that addresses social needs and the important upstream factors that influences health outcomes.

addressing the social needs of children attending a weight management program. the specific aims of this pilot randomized controlled trial are the following: 1. to determine the feasibility of implementation and delivery of a screening-referral intervention versus usual care to address social needs of children with obesity enrolled in a pediatric weight management program at mcmaster children's hospital, which will include recruitment rates, uptake of the intervention, and follow-up of participants. 2. to understand impact on health outcomes of a screening-referral intervention versus usual care to address social needs of children with obesity enrolled in a pediatric weight management program including change in i) body mass index z score (zbmi); ii) change in body composition; and iii) change in health-related quality of life. hypothesis: we hypothesize that health outcomes of children with obesity are connected to the social determinants of health, and that an intervention which screens for and refers to community supports will improve child obesity outcomes.

Eligibility criteria:
inclusion criteria: * enrollment in the weight management program exclusion criteria: * children in the care of child protection services and/or living in group or foster care. children in these settings will not be living within typical family-systems to have social needs addressed by this intervention. * parents who cannot read and write in english

Keywords: social determinants of health obesity child health social needs
the impact of the muse meditation device on student registered nurse anesthetists

Conditions: Stress; Anxiety; Affect; Burnout, Professional

Summary: the question this study is designed to answer is whether or not the use of a muse meditation device lowers student registered nurse anesthetist's perception of stress, anxiety, and burnout within the mayo clinic doctorate of nurse anesthesia practice program.


Eligibility criteria:
inclusion criteria: * student registered nurse anesthetists at mayo clinic in the class of 2021 and 2022. exclusion criteria: * student registered nurse anesthetists at mayo clinic who are not in the class of 2021 and 2022.
healthsnap on epicardial adipose tissue study

Conditions: Obesity; Pre Diabetes

Summary: the purpose of this research study is to learn about the effectiveness of healthsnap assessment, to reduce epicardial fat thickness. excessive epicardial fat is associated with higher risk of developing diabetes and heart diseases. healthsnap assessment is a simple, quick and not invasive tool that will provide the patient with a personalized information nutritional and exercise plan.the use of healthsnap in the clinical practice has not been evaluated, yet.

this study will evaluate the practicality of adding the healthsnap algorithm to the standard care of patients with overweight/obesity and pre-diabetes. participants will be recruited among the outpatient population who routinely refer to the lennar foundation comprehensive diabetes center outpatient clinics, division of endocrinology, diabetes and metabolism university of miami, for standard care and management of diabetes, obesity, overweight, hypertension, dyslipidemia. once patient eligibility and written consent are obtained, participant is then scheduled for the clinic visit through the university of miami uchart (epic) electronic system. the visits will be coordinated by the research coordinator. at each visit each patient will undergo: * full physical examination, body weight, height, waist and hip circumference, blood pressure (standard of care) * fasting blood glucose and haemoglobina1c (hba1c), lipid panel, comprehensive metabolic panel, fasting insulin, c-peptide and pro-insulin (all procedures are standard of care) * ultrasound assesment of epicardial fat, performed on site * healthsnap assessment performed on site (if randomized to the group receiving additional healthnap) * standard of care dietary counselling performed on site by a registered dietitian (if randomized to the control group) study patients and controls will be contacted by the dietitian and/or healthsnap supervisor once a week via telephone, or email (uchart) or via online session (collaborate ultra) to monitor their compliance and adherence to the exercise and dietary program.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) ≥ 27 kg/m2 * hba1c 5.7-6.5% within 3 months the initial visit and/or * fasting blood glucose (fbg) 100-125 mg/dl within 3 months the initial visit and/or * family history for diabetes or cad or dyslipidemia exclusion criteria: * • type 1 diabetes * pregnancy * mental illness preventing correct use of healthsnap * physical inability to follow healthsnap recommendations * active infective and neoplastic diseases * no current diabetes medications with the exception of metformin * chemotherapy

Keywords: epicardial fat
hemodynamic impact of cytosorb and ckrt in children with septic shock

Conditions: Septic Shock

Summary: impact of the hemoadsorption with cytosorb on hemodynamic in pediatric patients with septic shock: a prospectic pediatric pilot study

prospective interventional pilot study included children with septic shock, weight ≥ 10 kgs and requiring continuous kidney replacement therapy. cytosorb (cytosorbents inc, new jersey, usa) cartridge was added to ckrt every 24 hours for a maximum of 96 hours. a control group of matched patients was also identified from an external database. the primary outcome of the study was the proportion of patients who achieved an equal or more than 50% relative reduction in vasopressors or inotropes dose from baseline to the end of treatment. secondary outcomes included doses of vasopressors and inotropes, hemodynamic and biological changes, changes in severity scores and 28-day mortality.

Eligibility criteria:
inclusion criteria: 1. children weighing ≥ 10 kg 2. septic shock as defined by the international pediatric consensus conference 3. need for continuous renal replacement therapy (crrt) = acute kidney injury defined by the kdigo criteria (16) and/or fluid overload ≥ 10% exclusion criteria: * refused consensus by parents * concomitant use of other extracorporeal blood purification techniques.

Keywords: pediatric septic shock blood purification aki pediatric critical care hemoperfusion ckrt
arterial stiffening as a predictor for diastolic cardiac dysfunction and hfpef

Conditions: Heart Failure With Preserved Ejection Fraction; Cardiovascular Morbidity

Summary: patients at risk for developing heart failure with preserved ejection fraction (hfpef) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and hfpef.


Eligibility criteria:
inclusion criteria: one or more of the following criteria: * age \> 60 years * arterial hypertension (rr systolic ≥ 140 mmhg or diastolic ≥ 90 mmhg or ≥ 2 antihypertensive drugs) * diabetes mellitus type i or ii * atrial fibrillation * chronic kidney disease (gfr \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or acr ≥ 30 mg/g) * bmi ≥ 30 kg/m2 * nyha ≥ ii * e/e' \> 8 exclusion criteria: * left ventricular ejection fraction \< 50 % * significant valve disease (grade iii or higher) * history of interventional or surgical valve repair * regional wall motion abnormalities * respiratory diseases as a known cause for dyspnea * atrial flutter or fibrillation during examination * hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy * history of heart transplantation
is hyaluronic acid gel effective on oral mucositis in children who receiving chemotherapy

Conditions: Oral Mucositis

Summary: oral mucositis (om) is a common side effect of systemic chemotherapy (ct) in cancer patients. the aim of this study was to investigate the effect of hyaluronic acid (ha) gel on om in children receiving ct.


Eligibility criteria:
inclusion criteria: * children who receive chemotherapy * hospitalized patient exclusion criteria: - allergy about using drugs

Keywords: mucositis hyaluronic acid